Sangamo Therapeutics (SGMO) to Release Earnings on Monday

Sangamo Therapeutics (NASDAQ:SGMO) is expected to be releasing its earnings data before the market opens on Monday, March 17th. Analysts expect Sangamo Therapeutics to post earnings of ($0.09) per share and revenue of $11.70 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Sangamo Therapeutics Trading Up 6.2 %

NASDAQ:SGMO opened at $0.98 on Friday. The stock has a market capitalization of $204.72 million, a price-to-earnings ratio of -1.31 and a beta of 1.49. The firm has a fifty day simple moving average of $1.10 and a two-hundred day simple moving average of $1.40. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18.

Analyst Ratings Changes

SGMO has been the topic of several research reports. StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Wells Fargo & Company reduced their price objective on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 31st. Truist Financial reduced their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, January 27th. Finally, Jefferies Financial Group lowered their price objective on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, December 31st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $5.80.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.